ReviewEuropean respiratory review : an official journal of the European Respiratory Society2024
Bronchiectasis in Asia: a review of current status and challenges.
Review in European respiratory review : an official journal of the European Respiratory Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07088926 (A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
Who cites it
17 citing papers in PubMed.
- Nasal nitric oxide combined with clinical features for preliminary screening of primary ciliary dyskinesia in bronchiectasis.The European respiratory journal · 2026Article
- Efficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trial.Pulmonary therapy · 2026Article
- Airway clearance management for bronchiectasis in China: a multicentre cross-sectional study from the Chinese bronchiectasis registry (BE-China).The Lancet regional health. Western Pacific · 2026Article
- Article
- Brensocatib-Another Therapeutic "Window of Opportunity" for Patients with Bronchiectasis.Journal of clinical medicine · 2026Review
- Mortality rate and affecting factors in bronchiectasis patients: a 10-year retrospective cohort study from Turkey.BMC pulmonary medicine · 2026Article
- Physical activity, sex differences, and functional exercise capacity in bronchiectasis: Insights from a South Asian cohort.PloS one · 2026Article
- From evidence to practice: What the 2025 European Respiratory Society Bronchiectasis Guideline means for India.Lung India : official organ of Indian Chest Society · 2026Article
- Serum TNF-α and the future of biomarker-enhanced prognostication in bronchiectasis: An Indian perspective.Lung India : official organ of Indian Chest Society · 2026Article
- Exploring the molecular mechanism of apigenin in treating bronchiectasis based on network pharmacology and molecular docking.Scientific reports · 2025Article
- Non-cystic fibrosis bronchiectasis in Taiwan.BMJ open respiratory research · 2025Observational
- Unveiling hidden culprits: new perspectives on bronchiectasis pathogens in Taiwan.ERJ open research · 2025Article
- Article
- Phenotypes and endotypes in bronchiectasis: a narrative review of progress toward precision medicine.Journal of thoracic disease · 2025Review
- Bidirectional pathogenesis between non-tuberculous mycobacteria and bronchiectasis: clinical insights, diagnostic challenges and future directions-Perspectives from South Asia.Frontiers in tuberculosis · 2025Review
- Neutrophil elastase activity in bronchial lavage fluid and the one-year follow-up outcomes in bronchiectasis patients: A multicenter prospective cohort study.Therapeutic advances in respiratory diseaseArticle
- Impact of rheumatoid arthritis, seropositivity and disease-modifying anti-rheumatic drugs on mortality risk in bronchiectasis.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent bronchiectasis studies from large-scale multinational, multicentre registries have demonstrated that the characteristics of the disease vary according to geographic region. However, most perspectives on bronchiectasis are dominated by data from Western countries. This review intends to provide an Asian perspective on the disease, focusing on the established registries in India, Korea and China. Asian patients with bronchiectasis are less likely to show female predominance and experience exacerbations, are more likely to be younger, have milder disease, and have fewer options for guideline-recommended treatment than those living in other global regions. Furthermore, Asian bronchiectasis patients demonstrate different comorbidities, microbiological profiles and unique endophenotypes, including post-tuberculosis and dry bronchiectasis. Notably, each Asian region reveals further geographic variations and inter-patient differences. Future studies are warranted to better characterise Asian patients with bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.